Treatment of Severe Pain and Opioid-induced Constipation: An Observational Study of Quality of Life, Resource Use, and Costs in Sweden

Frida Hjalte, Gunnel Ragnarson Tennvall, Karl-Olof Welin, Dagmar Westerling, Frida Hjalte, Gunnel Ragnarson Tennvall, Karl-Olof Welin, Dagmar Westerling

Abstract

Introduction: Opioid-induced constipation (OIC) is a common and costly side effect of opioid treatment affecting patients' quality of life (QoL). The combination oxycodone/naloxone reduces OIC while providing effective analgesia in patients with moderate to severe pain. The objective of this observational study was to compare health-related quality of life (HRQoL), healthcare resource use, and costs in patients with severe pain who were initially treated with oxycodone and laxatives and then subsequently switched to treatment with oxycodone/naloxone.

Methods: Data were collected by means of questionnaires completed by patients with OIC before and after the initiation of oxycodone/naloxone treatment at different clinical centers in Sweden. The questionnaires included questions on healthcare resource use and absence from work and also consisted of the Patient Assessment of Constipation-QoL (PAC-QoL) instrument, the EuroQol five dimensions questionnaire (EQ-5D), the Patient Assessment of Constipation Symptoms (PAC-SYM) instrument, and the Bowel Function Index (BFI).

Results: The analysis included 37 patients. Resource utilization was lower after treatment with oxycodone/naloxone, in terms of both the number of healthcare contacts and the purchases of medicine for the treatment of constipation. According to the BFI score, patients had fewer problems with OIC after the initiation of oxycodone/naloxone. The PAC-QoL score showed a positive change for patients in both the 96-point dissatisfaction index and the 16-point satisfaction index. PAC-SYM scores was lower after the initiation of oxycodone/naloxone treatment, indicating fewer constipation-related problems.

Conclusion: Treatment with oxycodone/naloxone had an overall positive effect on patients, consisting mainly of decreasing the severity of the constipation problems, increasing HRQoL, and decreasing the use of healthcare resources.

Funding: Mundipharma AB, Gothenburg, Sweden.

Keywords: Costs; Laxatives; Naloxone; Opioid-induced constipation; Oxycodone; Quality of life; Resource use; Severe pain; Sweden.

Figures

Fig. 1
Fig. 1
Observation period

References

    1. Bruera E, Paice JA. Cancer pain management: safe and effective use of opioids. Am Soc Clin Oncol Educ Book. 2015:e593–599.
    1. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA. 2016;315(15):1624–1645. doi: 10.1001/jama.2016.1464.
    1. McNicol E. Opioid side effects and their treatment in patients with chronic cancer and noncancer pain. J Pain Palliat Care Pharmacother. 2008;22(4):270–281. doi: 10.1080/15360280802537225.
    1. Hjalte F, Berggren A-C, Bergendahl H, Hjortsberg C. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manag. 2010;40(5):696–703. doi: 10.1016/j.jpainsymman.2010.02.019.
    1. Lowenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10(4):531–543. doi: 10.1517/14656560902796798.
    1. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012;26(1):50–60. doi: 10.1177/0269216311418869.
    1. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–1108. doi: 10.1097/00005650-199711000-00002.
    1. Sharma S, Agarwal B. Scoring systems in evaluation of constipation and obstructed defection syndrome (ODS) J Int Med Sci Acad. 2012;25(1):57–59.
    1. Apoteket AB. . Accessed 11 Oct 2015.
    1. FASS Pharmaceutical Specialties in Sweden 2015. . 2015. Accessed 11 Oct 2015.
    1. Southern Regional Health Care Committee. Regional prices and payments for the Southern Healthcare Region in 2015 [Regionala priser och ersättningar för Södra Sjukvårdsregionen 2015]. . 2015. Accessed 11 Oct 2015.
    1. Sveriges riksbank (Swedish National Bank). Interests and exchange rates 2015. . Accessed 7 Jan 2016.
    1. Brooks A, Kominek C, Pham TC, Fudin J. Exploring the use of chronic opioid therapy for chronic pain: when, how, and for whom? Med Clin N Am. 2016;100(1):81–102. doi: 10.1016/j.mcna.2015.08.010.
    1. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–130. doi: 10.1016/j.jpain.2008.10.008.
    1. Rentz AM, Yu R, Muller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12(4):371–383. doi: 10.3111/13696990903430481.
    1. Morlion B, Clemens KE, Dunlop W. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone. Clin Drug Investig. 2015;35(1):1–11. doi: 10.1007/s40261-014-0254-6.
    1. Dunlop W, Uhl R, Khan I, Taylor A, Barton G. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ. 2012;15(3):564–575. doi: 10.3111/13696998.2012.665279.
    1. Goeree R, Goeree J. Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada. J Med Econ. 2016;19(3):277–291. doi: 10.3111/13696998.2015.1116992.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する